Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.
about
Creating an effective clinical registry for rare diseasesPrimary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health PerspectiveHow Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialistsDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesThe Immunogenetics of Autoimmune CholestasisRisk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis.Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitisA comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II.Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis.Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBDPrimary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.Liver Transplantation for Cholestatic Liver Diseases in AdultsPrimary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing CholangitisGenetic Abnormalities in Biliary Brush Samples for Distinguishing Cholangiocarcinoma from Benign Strictures in Primary Sclerosing CholangitisOutcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.Malignancies in Primary Sclerosing Cholangitis--A Continuing ThreatRisk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study-CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study INational incidence of autoimmune liver diseases and its relationship with the human development index.Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.Surgical treatment of intrahepatic cholangiocarcinoma in the USA.Outcomes in liver transplantation: does sex matter?Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.Screening for malignancy in primary sclerosing cholangitis (PSC).Inflammatory Bowel Disease with Primary Sclerosing Cholangitis: a Danish Population-based Cohort Study 1977-2011.Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.Primary sclerosing cholangitis: a clinical update.Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.The management of autoimmunity in patients with cholestatic liver diseases.The Management of Acute Pancreatitis in the Pediatric Population: A Clinical Report from the NASPGHAN Pancreas Committee.New approach to decrease post-ERCP adverse events in patients with primary sclerosing cholangitis.Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?Recommendations on the use of MRI in PSC-A position statement from the International PSC study group.Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.
P2860
Q26741126-A3EE2C66-D600-4557-A326-DA05389C32EDQ26781780-E4C682A6-02A7-4870-B662-FDB83C89D1F3Q26782878-2812A726-570E-44F8-9B7F-81C271B237DAQ26796355-4AA62865-4891-4DE4-8732-625FDDC45EB5Q28085134-3903BA96-4161-424D-809E-41DA58C6E44FQ28085346-CFFEE490-966C-4894-86E5-5F4835C7E597Q34403316-37458A47-1FBF-4BF4-A938-2C8C9AF16C1FQ35146460-1DD2EF04-39D1-4810-9CBD-37E64D47D499Q35470575-E5C59234-622C-42D4-ABE4-516F7CAFEADAQ35535485-55743CCB-4C9A-460B-A6A0-343ACE6409C6Q35810359-E9C85838-D768-44D5-AE9C-01A8F868105EQ36025017-BF5E5B2A-498B-4FE7-82FA-BCE89DE156A6Q36199767-AAE1CA26-B6BC-44F4-A92E-C2C73ECFA7E5Q36320523-525C09C6-27D9-4620-A3F5-B3179872CF81Q36325130-B5A597C3-4D04-4FD9-AD2F-ED346856AE94Q36693626-47E27862-0773-4B54-88B6-4784ECE11409Q36752084-9455ADAF-69CC-47F1-80B4-29E190AA3A3CQ36805289-D50D9985-5039-4B9D-AC3D-53BAE7396DB8Q37000684-0EACA19C-1DBF-46BC-9DAE-A013922595B3Q37082378-3DE20BBA-FFE7-4EB5-A8C7-FB3BE4DFAEA5Q37454003-82BDD75E-B98F-4386-9BAF-30C9962EB585Q37564713-E7B5CA95-08E7-438B-870C-C8C59C0FD5A4Q37584099-6D49D2A2-2AE6-4E77-B284-DE2B4FA5A9F4Q37710785-EB15A247-39D5-42B7-BD34-623401A65302Q38174167-8F57A285-CD7C-413D-9FA6-ED3D475EB890Q38245994-8500BAAF-0ACD-43E3-8E8E-2E0BCE96E567Q38272589-2C99D598-E3C4-444F-9A2A-5F3A81881977Q38356761-565035BC-D5D9-47A4-9305-0979C84C7F66Q38374581-93AA8AEE-7CDA-49B6-B36E-0B192C257B66Q38383074-C6C24298-E8C7-44B1-9413-5E5CF75CB259Q38399155-D219014E-58D7-4092-B8A7-47089E0D4174Q38412069-A6F946C0-3926-4CD4-925F-81212BD608D9Q38485235-B1C35E13-BB77-4971-93C7-F0AF76FAD4BEQ38595151-2EED0635-4FF0-408F-95C6-38C6EA47FF1CQ38622370-70E00505-D769-460F-8286-FC0371A3ADAEQ38637770-3A44289B-96AA-4A86-A4A5-0F4A5D73CE0AQ38645109-331DFA89-98C8-4F9D-9780-21412071E463Q38657903-CDB68C99-9FE4-4FF0-975A-DB87DDEFD9AEQ38677506-7F1D6C46-CF6C-4E2A-8DC4-70B549267FD8Q38732987-02C97054-BCE9-43AC-A1ED-0A335C65F2BF
P2860
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@ast
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@en
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@nl
type
label
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@ast
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@en
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@nl
prefLabel
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@ast
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@en
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@nl
P2093
P2860
P356
P1433
P1476
Population-based epidemiology, ...... rimary sclerosing cholangitis.
@en
P2093
Alexander C Poen
Anton H Naber
B W Marcel Spanier
Bart van Hoek
Ben J Witteman
Cyriel Y Ponsioen
EpiPSCPBC Study Group
Erik A Rauws
Frank P Vleggaar
Hans A Tuynman
P2860
P304
P356
10.1002/HEP.26565
P407
P577
2013-10-17T00:00:00Z